MediWound’s NexoBrid commercially available in the U.S. for thermal burns

MediWound announced the U.S. commercial availability of NexoBrid for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns. Eschar removal is a critical first step in the treatment of burns as it can reduce inflammation, stop burn progression, as well as mitigate infections and sepsis. NexoBrid selectively targets eschar while preserving viable tissue.